Other · developed by Novo Nordisk
NNC4004-0002 is an agent given subcutaneously, studied as a single ascending dose in healthy volunteers and in hyperuricemia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06859073 | Phase 1 | Healthy Volunteers | Active not recruiting | NVO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy VolunteersHyperuricemia
Updated Nov 8, 2026. Something wrong or missing? Report it on the NVO page.
See NVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVO catalysts and pipeline →